Antineoplaston Therapy in Treating Patients With Brain Tumors
NCT00003457
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
40
Enrollment
OTHER
Sponsor class
Conditions
Refractory Brain Tumors
Interventions
DRUG:
Antineoplaston therapy (Atengenal + Astugenal)
Sponsor
Burzynski Research Institute